IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings

Ital J Neurol Sci. 1997 Aug;18(4):191-4. doi: 10.1007/BF02080463.

Abstract

IL-10 is a cytokine with suppressive effects on (auto) antigen presentation and T-cell-mediated immune reactions, but is also capable of stimulating polyclonal IgG synthesis. Recent evidence suggests its involvement in multiple sclerosis (MS) and systemic lupus erythematosus (SLE). We assessed PBMNC IL-10 release in MS and SLE patients before and after in vivo prednisone or methylprednisolone treatment. The SLE patients showed a high level of IL-10 release by unstimulated PBMNCs, whereas the PHA-stimulated PBMNCs from MS patients produced large amounts of the cytokine.

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • Female
  • Humans
  • Interleukin-10 / biosynthesis*
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / metabolism*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / metabolism*
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism*
  • Prednisone / therapeutic use

Substances

  • Interleukin-10
  • Prednisone
  • Methylprednisolone